마바콕시브
Mavacoxib
4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide
다른 이름: Trocoxil · mavacoxibum · PHA 739,521 · UNIIYFT7X7SR77
VetSheet 수의사 팀 검수업데이트 2026년 4월 5일근거 기반 수의학 참고자료
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
동물 종별 용량
🌎 NA — North America🌍 EU — Europe
개
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| Pain and inflammation associated with degenerative joint disease in dogs aged 12 months or more in cases where continuous treatment exceeding one month is indicated | 2 mg/kg PO given immediately before or with the dog's main meal. The treatment should be repeated 14 days later; thereafter the dosing interval is one month. | PO | Day 1, Day 14, then monthly | A treatment cycle should not exceed 7 consecutive doses (6.5 months). | 🌎 NA |
| Pain and inflammation associated with degenerative joint disease (osteoarthritis) | 2 mg/kg | PO | q14d for 2 doses, then q1month | Maximum of 7 doses total | 🌍 EU |
- Pain and inflammation associated with degenerative joint disease in dogs aged 12 months or more in cases where continuous treatment exceeding one month is indicated: Care should be taken to ensure that the tablet is ingested. THIS IS not a daily NSAID.
- Pain and inflammation associated with degenerative joint disease (osteoarthritis): Should be given immediately before or with the dog's main meal. Treatment can potentially be re-started after a 1-month break from dosing.
고양이
| 적응증 | 용량 | 경로 | 빈도 | 기간 | 지역 |
|---|---|---|---|---|---|
| Any | Do not use | PO | N/A | N/A | 🌍 EU |
- Any: Contraindicated in cats.
용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.
개요
마바콕시브(Mavacoxib)는 콕시브 계열의 매우 독특한 초장기 작용 비스테로이드성 항염증제(NSAID)입니다. 매일 투여하는 기존의 NSAID와 달리 월 1회 투여하도록 설계되어 매일 약을 먹이기 어려운 보호자에게 훌륭한 대안이 됩니다.
임상 요점: 반감기가 매우 길기 때문에(평균 16~17일) 부작용이 발생할 경우 투약 중단 후에도 수주간 지속될 수 있습니다. 따라서 신중한 환자 선택이 필수적이며, 일반적으로 급성 통증보다는 만성 골관절염 관리에 사용됩니다.
작용 기전
Mavacoxib is a COX-2 selective inhibitor (coxib).
- Arachidonic Acid Cascade: It selectively inhibits the cyclooxygenase-2 (COX-2) enzyme → decreases the production of pro-inflammatory prostaglandins (such as PGE2) → reduces pain, inflammation, and fever.
- COX-1 Sparing: At therapeutic dosages, it relatively spares COX-1, the constitutive enzyme responsible for synthesizing prostaglandins that protect the gastric mucosa, support platelet function, and maintain normal renal blood flow. However, COX-selectivity is relative and can be lost at higher doses or in susceptible individuals.
안전성·주의사항
금기사항
- Dogs less than 12 months of age
- Dogs less than 5 kg body weight
- Gastrointestinal disorders including ulceration and bleeding
- Evidence of a hemorrhagic disorder
- Impaired renal or hepatic function
- Cardiac insufficiency
- Hypersensitivity to mavacoxib, sulfonamides, or excipients
- Pregnant, breeding, or lactating animals
- Dehydrated, hypovolemic, or hypotensive animals
- Dehydrated, hypovolaemic, or hypotensive patients
- Gastrointestinal disease or ulceration
- Blood clotting disorders
- Liver disease (prolongs metabolism and causes accumulation)
- Renal disease (requires careful evaluation, generally avoid)
- Pregnant or lactating animals
- Dogs < 12 months of age
- Dogs < 5 kg body weight
- Cats
부작용
- Inappetence
- Diarrhea
- Depression
- Gastrointestinal ulceration or bleeding
- Vomiting and diarrhoea
- Renal toxicity (especially if dehydrated or hypotensive)
- Hepatic accumulation (in poor metabolizers)
- Theoretical risk of precipitating cardiac failure
주의
Do not use concomitantly with glucocorticoids or other NSAIDs. Do not administer other NSAIDs within 1 month of the last administration of mavacoxib. Avoid use in any dehydrated, hypovolemic, or hypotensive animal, as there is a potential risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic medicinal products should be avoided. Animals should not become dehydrated when receiving this or other NSAIDs.
약물 상호작용
NSAIDs can reduce effects on blood pressure and potentially reduce renal blood flow, increasing the risk for renal injury.
May increase the risk of gastrointestinal toxicity (ulceration, bleeding, vomiting, diarrhea). Long washout periods are warranted when switching.
May increase the risk of gastrointestinal toxicity (ulceration, bleeding, vomiting, diarrhea). Concurrent use is contraindicated.
NSAIDs may increase serum levels of digoxin.
May increase plasma levels of mavacoxib (extrapolated from celecoxib data in humans).
NSAIDs may reduce saluretic and diuretic effects.
Serious toxicity has occurred when NSAIDs have been used concomitantly; use together with extreme caution.
May enhance the risk of nephrotoxicity development.
May increase the risk of gastrointestinal toxicity. Do not administer other NSAIDs within 1 month of the last administration of mavacoxib.
Increased risk of severe gastrointestinal ulceration and bleeding.
Increased risk of nephrotoxicity.
Synergistic risk of acute kidney injury.
모니터링
- Baseline and periodic CBC and serum chemistry (including BUN/serum creatinine, and liver function assessment)
- Baseline history and physical
- Efficacy of therapy
- Adverse effect monitoring via client
- Baseline and periodic renal function (BUN, Creatinine, SDMA, USG)
- Baseline and periodic hepatic function (ALT, ALP, Bilirubin)
- Clinical signs of GI ulceration (vomiting, melaena, anorexia)
- Hydration status and blood pressure (especially during anaesthesia)
약동학
반감기
흡수
Average bioavailability after oral dosing is about 46% when fasted, but nearly doubles (87%) when given with food. Peak levels occur in about 11 hours.
분포
Apparent volume of distribution (steady-state) averaged 1.6 L/kg. Highly bound to canine plasma proteins (98%).
대사
Primarily cleared by biliary excretion.
배설
Total body clearance is a very low 2.7 mL/hour/kg.
과다투여
In safety studies, repeated doses of 5 and 10 mg/kg did not demonstrate adverse events. At 15 mg/kg, vomiting, softened/mucoid feces, and decreased renal function were noted. Doses of 25 mg/kg caused GI ulceration, with one fatality from GI perforation and peritonitis.
- Management: Manage as with other NSAID toxicity (emetics, activated charcoal, GI protectants, fluid diuresis).
- Important: Because of the drug's very long duration of effect, prolonged monitoring and treatment may be required. Consulting a veterinary poison center is highly recommended.
제품
제형
- Oral chewable tablets
- 6 mg chewable tablet
- 20 mg chewable tablet
- 30 mg chewable tablet
- 75 mg chewable tablet
- 95 mg chewable tablet
동물용의약품
- Mavacoxib Oral Chewable Tablets: 6 mg, 20 mg, 30 mg, 75 mg, & 95 mg (Trocoxil)
- Trocoxil 6 mg chewable tablets
- Trocoxil 20 mg chewable tablets
- Trocoxil 30 mg chewable tablets
- Trocoxil 75 mg chewable tablets
- Trocoxil 95 mg chewable tablets
규제 현황
Authorized for use in dogs >= 12 months old.
POM-V classification.
규제 데이터 없음: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
보관·안정성
Store in the original packaging at room temperature out of reach of pets and children.
보호자 정보
매우 중요: 이 약은 매일 먹이는 약이 아닙니다. 수의사가 지시한 일정(일반적으로 1일차, 14일차 투여 후 엄격하게 월 1회)에 맞춰 정확히 투여하십시오. 임의로 추가 투여하지 마십시오.
- 식사와 함께 투여: 반려견의 하루 중 가장 많은 양의 식사와 함께 먹이십시오. 음식과 함께 먹일 때 위장에서의 약물 흡수율이 훨씬 높아집니다.
- 부작용 관찰: 식욕 부진, 구토, 혈변 또는 검은색/타르색 변, 행동 변화, 음수량 또는 배뇨량의 변화가 관찰되면 즉시 수의사에게 연락하십시오. 참고: 이 약은 체내에 오래 머물기 때문에 마지막 투여 후 수주가 지나서 부작용이 발생할 수도 있습니다.
- 안전한 보관: 이 츄어블 정제는 기호성이 매우 높습니다. 우발적인 과다 복용을 방지하기 위해 모든 반려동물과 어린이의 손이 절대 닿지 않는 곳에 보관하십시오.
VetSheet 의약품 참고자료는 수의사 전문가의 임상 의사결정 지원을 위한 것이며, 전문적 판단이나 제조사의 최신 약물 정보를 대체할 수 없습니다.